Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer.

Buckner, Jan C; Forouzesh, Bahram; Erlichman, Charles; Hidalgo, Manuel; Boni, Joseph P; Dukart, Gary; Berkenblit, Anna; Rowinsky, Eric K

Buckner, Jan C; Forouzesh, Bahram; Erlichman, Charles; Hidalgo, Manuel; Boni, Joseph P; Dukart, Gary; Berkenblit, Anna; Rowinsky, Eric K.

Affiliation

Buckner JC; Mayo Clinic, Rochester, MN, USA. buckner.jan@mayo.edu

Invest New Drugs ; 28(3): 334-42, 2010 Jun.

Article in En | MEDLINE | ID: mdl-19415181

Subject(s)

Antineoplastic Agents/administration & dosage; Antineoplastic Agents/pharmacokinetics; Intracellular Signaling Peptides and Proteins/antagonists & inhibitors; Neoplasms/drug therapy; Protein Serine-Threonine Kinases/antagonists & inhibitors; Sirolimus/analogs & derivatives; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents/adverse effects; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Sirolimus/administration & dosage; Sirolimus/adverse effects; Sirolimus/pharmacokinetics; TOR Serine-Threonine Kinases; Treatment Outcome

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Protein Serine-Threonine Kinases / Sirolimus / Intracellular Signaling Peptides and Proteins / Neoplasms / Antineoplastic Agents Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Invest New Drugs Year: 2010 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google